IRF8 and acute lymphoblastic leukemia: Moreover, the therapeutic function of FB23‐2 was significantly reversed by the downregulation of IRF8, indicating that IRF8 is indispensable to achieving the therapeutic efficacy of FB23‐2 in T‐ALL.